Global Reach Aurobindo Pharma operates across more than 150 countries and is the largest generic pharma company in the US, presenting ample opportunities to cross-sell manufacturing, APIs, and contract development services to a broad set of international buyers and distributors.

Biologics Expansion Recent foray into biologics with TheraNym and a US$126 million Telangana biologics CDMO facility signals readiness to offer biologics CMO/CMO-derived services, enabling sales conversations around biosimilars, complex biologics manufacturing, and related clinical development support.

Regulatory Stronghold With 30+ facilities approved by USFDA, MHRA, EDQM, PMDA, WHO, and others, Aurobindo’s breadth of GMP-certified capacity supports high-quality API and generic production, creating sales leverage for partners seeking compliant, scalable manufacturing with regulatory confidence.

Strategic Investments Large-scale capital deployments in Telangana and ongoing facility expansions indicate a growth engine and potential for long-term supply agreements, technology transfers, and co-development deals with pharmaceutical brands seeking expanded capacity.

Diversified Portfolio Strong multi-therapeutic footprint (CNS, ARV, CVS, antibiotics, GI, anti-diabetics, oncology, dermatology) combined with API and generic strengths creates cross-sell opportunities for contract manufacturing, supply agreements, and integrated drug development partnerships.